Supply of products by Merck Sharpe & Dohme

Overview

The Therapeutic Goods Act 1989 was enacted to regulate the quality, efficacy, and safety of therapeutic goods in Australia. In addressing gaps in the previous regulatory framework, the Act aimed to provide a comprehensive legislative basis for the oversight of therapeutic goods, including medicines, medical devices, and related products. The Act was passed by the Australian Parliament and sought to ensure that therapeutic goods available in the market are of acceptable quality and pose minimal risk to consumers. In June 2013, the delegate of the Secretary of the Department of Health and Ageing gave consent under sections 14 and 14A of the Act for the supply of certain hepatitis B vaccines that did not conform to certain labelling requirements under Therapeutic Goods Order 69. This consent was granted subject to specific conditions, ensuring the products' supply would continue for the life of the current vial labels without any changes to the products themselves.

Scope and Application

The Therapeutic Goods Act 1989 governs the regulation of therapeutic goods in Australia, encompassing a wide range of products including medicines, medical devices, blood, and tissues. Section 14 and 14A of the Act specifically address the consent required for the supply of therapeutic goods that do not conform with certain standards or requirements set out in Therapeutic Goods Orders. The Act applies to entities and individuals involved in the supply of therapeutic goods within Australia, with its jurisdiction extending across the Commonwealth. The provided consent applies to the supply of specific hepatitis B vaccines produced and supplied by Merck Sharpe & Dohme. This consent is limited to the life of the current vial labels, ensuring compliance with the Act while allowing the supply of these vaccines despite their non-conformity with certain labelling requirements under TGO 69. The consent is subject to conditions that no other changes have been made to the products, thus maintaining the integrity and safety of the therapeutic goods in question.

Key Provisions

The Therapeutic Goods Act 1989, particularly sections 14 and 14A, grants the delegate of the Secretary of the Department of Health and Ageing the authority to consent to the supply of certain therapeutic goods that do not fully comply with existing Therapeutic Goods Orders (TGO). In this instance, section 14(1) allows the delegate to consent to the supply of specified hepatitis B vaccines by Merck Sharpe & Dohme, which do not adhere to paragraphs 3(2)(b) and 3(2)(c) of TGO 69. This means that the labels of these vaccines do not include the names of all active ingredients and their respective quantities or proportions. Despite this non-compliance, the delegate has granted permission for the continued supply of these vaccines, as stated in subsection 15(1) of the Act. Under the Act, the delegate’s consent comes with specific conditions to ensure that the therapeutic goods in question remain safe and effective for their intended use. Firstly, the consent applies only for the duration that the current vial labels remain in use. This means that any future changes to the product, including the labels, would require a new assessment and consent. Secondly, the delegate has explicitly stated that no other changes have been made to the products beyond the labelling issue. This ensures that the therapeutic goods themselves have not been altered in a way that could compromise their safety or efficacy. The Therapeutic Goods Act 1989 also imposes obligations on the parties involved in the supply of these therapeutic goods. The delegate of the Secretary must ensure that the consent granted does not pose any undue risk to public health. This includes monitoring the products to confirm that they meet the necessary safety and efficacy standards despite the labelling issue. The company, Merck Sharpe & Dohme, must adhere to the conditions set forth in the consent, such as maintaining the current labelling until it is replaced. Failure to comply with these obligations could result in legal consequences. Additionally, the Act stipulates potential penalties and consequences for non-compliance. Under the Act, breaches of certain provisions can lead to both civil and criminal penalties. For example, supplying therapeutic goods that do not comply with the Act or the conditions of any consent given under it can result in fines and imprisonment. The maximum penalties can vary depending on the severity and intent of the breach, but they serve as a deterrent against non-compliance. It is therefore crucial for all parties involved to strictly adhere to the terms and conditions set forth in the Act and any consent granted under it.